Abstract |
For the treatment of Hodgkin lymphoma, bispecific monoclonal antibodies (bi-mAbs) were established which recognize the Hodgkin-associated CD30 antigen with one arm and the CD3 or CD28 antigen on T lymphocytes or the CD16 antigen on natural killer (NK) cells with the second arm. The NK cell-activating alpha-CD16/CD30 antibody was able to retarget human NK cells toward CD30- target cells and induce their lysis. Sixty percent of Hodgkin tumor-bearing severe combined immunodeficient mice responded to a combined treatment with bi-mAb and human NK cells, leading to a final cure rate of 20%. T cell-activating bi-mAbs were more effective, resulting in the cure of all mice treated. The in vivo administration of both alpha-CD3/CD30 and alpha-CD28/CD30 antibodies resulted in the specific activation of resting human T cells infiltrating the CD30+ Hodgkin tumors. Tumor-infiltrating lymphocytes in the group of mice treated with both T cell-activating bi-mAbs expressed high levels of cytokines and cytotoxic molecules such as perforin and the cytotoxic serine esterases granzyme A and B. More importantly, activated T cells did not home to CD30 tissue and did not enter the circulation. Encouraged by these preclinical data, 15 patients with treatment-refractory Hodgkin lymphoma were included in a phase I/II dose-escalation study and treated four times every 3 or 4 days with increasing doses of the alpha-CD16/CD30 bi-mAb ranging from 1 mg/m2 to 128 mg/m2. No dose-limiting toxicity occurred even at the highest doses. Of these 15 patients, one had a complete response, one a partial response, three a mixed response, two stable disease, and eight patients had progressive disease. Treatment with immunological effector cell-recruiting bi-mAbs is a promising new approach to the treatment of Hodgkin disease refractory to standard therapy.
|
Authors | L da Costa, C Renner, F Hartmann, M Pfreundschuh |
Journal | Cancer chemotherapy and pharmacology
(Cancer Chemother Pharmacol)
Vol. 46 Suppl
Pg. S33-6
( 2000)
ISSN: 0344-5704 [Print] Germany |
PMID | 10950145
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antibodies, Bispecific
- Antibodies, Monoclonal
- CD28 Antigens
- CD3 Complex
- Ki-1 Antigen
- Receptors, IgG
|
Topics |
- Animals
- Antibodies, Bispecific
(immunology, therapeutic use)
- Antibodies, Monoclonal
(immunology, therapeutic use)
- CD28 Antigens
(immunology)
- CD3 Complex
(immunology)
- Hodgkin Disease
(immunology, therapy)
- Humans
- Ki-1 Antigen
(immunology)
- Killer Cells, Natural
(immunology)
- Lymphocyte Activation
(immunology)
- Mice
- Mice, SCID
- Neoplasm Transplantation
- Receptors, IgG
(immunology)
- Reed-Sternberg Cells
(immunology)
- T-Lymphocytes
(immunology)
- Tumor Cells, Cultured
|